[Efficacy of controlled-release oxycodone for dyspnea in cancer patients--three case series]
- PMID: 16612168
[Efficacy of controlled-release oxycodone for dyspnea in cancer patients--three case series]
Abstract
Dyspnea is a common symptom in patients with advanced cancer. Systemic morphine administration has been reported as an effective pharmacological treatment to control dyspnea. However, there have been few reports on similar effects of alternative opioids except for morphine. To evaluate the effect of controlled-release oxycodone on the relief of dyspnea, we investigated three cases with opioid substitution from subcutaneous morphine to oral oxycodone. In all cases, both opioids provided equivalent effects for the palliation of cancer dyspnea with no significant adverse effects. Future studies in the appropriate clinical designs will be needed to confirm our findings.
Similar articles
-
Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).Pain Pract. 2008 Jul-Aug;8(4):287-313. doi: 10.1111/j.1533-2500.2008.00204.x. Epub 2008 May 23. Pain Pract. 2008. PMID: 18503626
-
Efficacy and tolerability of cancer pain management with controlled-release oxycodone tablets in opioid-naive cancer pain patients, starting with 5 mg tablets.Jpn J Clin Oncol. 2004 Oct;34(10):608-14. doi: 10.1093/jjco/hyh104. Jpn J Clin Oncol. 2004. PMID: 15591459 Clinical Trial.
-
Nebulized versus subcutaneous morphine for patients with cancer dyspnea: a preliminary study.J Pain Symptom Manage. 2005 Jun;29(6):613-8. doi: 10.1016/j.jpainsymman.2004.08.016. J Pain Symptom Manage. 2005. PMID: 15963870 Clinical Trial.
-
[Home hospice care for the lung cancer patients].Gan To Kagaku Ryoho. 2009 Dec;36 Suppl 1:81-3. Gan To Kagaku Ryoho. 2009. PMID: 20443410 Japanese.
-
Normal-release and controlled-release oxycodone: pharmacokinetics, pharmacodynamics, and controversy.Support Care Cancer. 2003 Feb;11(2):84-92. doi: 10.1007/s00520-002-0385-9. Epub 2002 Aug 23. Support Care Cancer. 2003. PMID: 12560936 Review.
Cited by
-
Safety and efficacy of oxycodone for refractory dyspnea in end-stage heart failure patients with chronic kidney disease: a case series of eight patients.J Pharm Health Care Sci. 2024 Oct 7;10(1):63. doi: 10.1186/s40780-024-00384-4. J Pharm Health Care Sci. 2024. PMID: 39375816 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical